The following FAQs address key methodological considerations for PAGE3 (GAGED1) antibody applications in academic research, synthesized from technical literature and product documentation. Common typographical variations (PAE3 vs. PAGE3) have been resolved using UniProt cross-referencing (Q5JUK9) .
Advanced troubleshooting matrix:
Source contradictions arise from:
Tissue-specific post-translational modifications (phosphorylation at Ser27 alters subcellular distribution)
Antibody lot variations in polyclonal preps (batch-to-batch epitope diversity)
Optimized workflow:
Crosslinker choice: Use DSP (dithiobis[succinimidyl propionate]) for membrane-associated complexes vs. EGS for nuclear interactions .
Electrophoresis: 16% Tris-Tricine gels to resolve <15 kDa proteins .
Blotting: 0.1 μm PVDF membranes with 20% methanol transfer buffer to retain small proteins.
Critical controls:
Include GAPDH spiking to detect proteolytic degradation
Validation cascade:
Data contradiction resolution: Discrepancies between IHC and ELISA typically stem from conformational epitope requirements. Solution: Use native PAGE for antigen preparation .
Advanced integration pipeline:
Spatial mapping: Align IHC H-scores with Visium HD spatial transcriptomics (10 μm registration) .
Proteogenomic bridging:
Validation loop: Use antibody-derived tags to refine pseudotime trajectories in SCENIC analyses.
Key challenge: Antibody signal decay (t1/2 = 8.3hr in live-cell imaging) requires synchronization with scRNA-seq timepoints .